These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39365875)

  • 1. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry.
    Zhou Y; Zhang Y; Li M; Ming T; Zhang C; Huang C; Li J; Li F; Li H; Zhao E; Shu F; Liu L; Pan X; Gao Y; Tian L; Song L; Huang H; Liao W
    Sci Immunol; 2024 Oct; 9(100):eado8758. PubMed ID: 39365875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling.
    Miyashita M; Oshiumi H; Matsumoto M; Seya T
    Mol Cell Biol; 2011 Sep; 31(18):3802-19. PubMed ID: 21791617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R.
    Boonyaratanakornkit J; Bartlett E; Schomacker H; Surman S; Akira S; Bae YS; Collins P; Murphy B; Schmidt A
    J Virol; 2011 Feb; 85(4):1495-506. PubMed ID: 21123378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current understanding on the impact of KRAS on colorectal cancer.
    Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
    Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glomerular endothelial expression of type I IFN-stimulated gene, DExD/H-Box helicase 60 via toll-like receptor 3 signaling: possible involvement in the pathogenesis of lupus nephritis.
    Karasawa T; Sato R; Imaizumi T; Hashimoto S; Fujita M; Aizawa T; Tsugawa K; Kawaguchi S; Seya K; Terui K; Tanaka H
    Ren Fail; 2022 Dec; 44(1):137-145. PubMed ID: 35392757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Choi H; Kwon J; Cho MS; Sun Y; Zheng X; Wang J; Bouker KB; Casey JL; Atkins MB; Toretsky J; Han C
    Cancer Res; 2021 Jul; 81(13):3607-3620. PubMed ID: 33941613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
    Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
    Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of antiviral innate immunity by birnavirus VP3 protein via blockage of viral double-stranded RNA binding to the host cytoplasmic RNA detector MDA5.
    Ye C; Jia L; Sun Y; Hu B; Wang L; Lu X; Zhou J
    J Virol; 2014 Oct; 88(19):11154-65. PubMed ID: 25031338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
    Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
    Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
    [No Abstract]   [Full Text] [Related]  

  • 15. DDX3 enhances oncogenic KRAS‑induced tumor invasion in colorectal cancer via the β‑catenin/ZEB1 axis.
    Wu DW; Lin PL; Cheng YW; Huang CC; Wang L; Lee H
    Oncotarget; 2016 Apr; 7(16):22687-99. PubMed ID: 27007150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
    Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
    Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
    Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
    J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Honokiol enhances the sensitivity of cetuximab in KRAS
    Zhu Q; Zhang R; Gu X; Zhao Z; Gao Q; Chen M; Wu Q; Xie T; Sui X
    Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106
    [No Abstract]   [Full Text] [Related]  

  • 19. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.